-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Short Interest in ATyr Pharma, Inc. (NASDAQ:LIFE) Grows By 5.4%
Short Interest in ATyr Pharma, Inc. (NASDAQ:LIFE) Grows By 5.4%
aTyr Pharma, Inc. (NASDAQ:LIFE – Get Rating) was the recipient of a large growth in short interest in the month of August. As of August 31st, there was short interest totalling 341,600 shares, a growth of 5.4% from the August 15th total of 324,000 shares. Based on an average daily trading volume, of 131,700 shares, the days-to-cover ratio is presently 2.6 days.
aTyr Pharma Stock Down 3.9 %
aTyr Pharma stock opened at $2.93 on Wednesday. The firm's fifty day moving average price is $3.49 and its two-hundred day moving average price is $3.76. aTyr Pharma has a 1-year low of $2.60 and a 1-year high of $13.10.
Get aTyr Pharma alerts:aTyr Pharma (NASDAQ:LIFE – Get Rating) last announced its quarterly earnings results on Monday, August 15th. The biotechnology company reported ($0.44) earnings per share for the quarter, missing the consensus estimate of ($0.43) by ($0.01). During the same quarter last year, the company earned ($0.64) EPS. Analysts anticipate that aTyr Pharma will post -1.81 earnings per share for the current fiscal year.
Insiders Place Their Bets
In related news, CEO Sanjay Shukla bought 15,000 shares of aTyr Pharma stock in a transaction that occurred on Friday, July 1st. The shares were acquired at an average cost of $2.88 per share, for a total transaction of $43,200.00. Following the completion of the acquisition, the chief executive officer now directly owns 40,798 shares of the company's stock, valued at approximately $117,498.24. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 4.36% of the company's stock.Hedge Funds Weigh In On aTyr Pharma
Several large investors have recently bought and sold shares of LIFE. Tikvah Management LLC bought a new stake in shares of aTyr Pharma in the 4th quarter worth $9,157,000. Deep Track Capital LP purchased a new stake in aTyr Pharma in the 4th quarter valued at about $8,217,000. Stonepine Capital Management LLC lifted its position in shares of aTyr Pharma by 28.0% during the 4th quarter. Stonepine Capital Management LLC now owns 525,531 shares of the biotechnology company's stock worth $3,926,000 after buying an additional 114,996 shares in the last quarter. Alyeska Investment Group L.P. boosted its stake in shares of aTyr Pharma by 12.7% in the 1st quarter. Alyeska Investment Group L.P. now owns 760,798 shares of the biotechnology company's stock worth $4,070,000 after buying an additional 85,823 shares during the last quarter. Finally, GSA Capital Partners LLP bought a new position in shares of aTyr Pharma in the fourth quarter valued at approximately $439,000. 65.58% of the stock is currently owned by institutional investors.
Wall Street Analyst Weigh In
A number of research firms have commented on LIFE. Piper Sandler raised their price target on shares of aTyr Pharma from $11.00 to $14.00 and gave the stock an "overweight" rating in a report on Monday, August 15th. StockNews.com lowered aTyr Pharma from a "hold" rating to a "sell" rating in a research report on Wednesday, September 14th. Finally, HC Wainwright increased their price target on aTyr Pharma from $11.00 to $35.00 and gave the stock a "buy" rating in a report on Thursday, July 21st.
About aTyr Pharma
(Get Rating)
aTyr Pharma, Inc, a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. The company's lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in Phase II clinical trial for pulmonary sarcoidosis; and in Phase 1b/2a clinical trial for treatment of other interstitial lung diseases (ILDs), such as chronic hypersensitivity pneumonitis and connective tissue disease related ILD.
Recommended Stories
- Get a free copy of the StockNews.com research report on aTyr Pharma (LIFE)
- 3 Defensive Stocks With 60-Year Dividend Hike Streaks
- 3 Airline Stocks Stuck in a Holding Pattern
- Roku Stock is Down but Not Out
- If You're Hungry for Value, Take a Bite on Ruth's Hospitality Grp
- Is Ford Rolling To A Rebound After Its Q3 Warning
Receive News & Ratings for aTyr Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for aTyr Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
aTyr Pharma, Inc. (NASDAQ:LIFE – Get Rating) was the recipient of a large growth in short interest in the month of August. As of August 31st, there was short interest totalling 341,600 shares, a growth of 5.4% from the August 15th total of 324,000 shares. Based on an average daily trading volume, of 131,700 shares, the days-to-cover ratio is presently 2.6 days.
ATyr制药公司(纳斯达克:LIFE-GET评级)在8月份获得了空头股数的大幅增长。截至8月31日,空头股数共有34.16万股,较8月15日的32.4万股增长5.4%。根据日均成交量131,700股,目前天数与回补比率为2.6天。
aTyr Pharma Stock Down 3.9 %
ATyr Pharma股价下跌3.9%
aTyr Pharma stock opened at $2.93 on Wednesday. The firm's fifty day moving average price is $3.49 and its two-hundred day moving average price is $3.76. aTyr Pharma has a 1-year low of $2.60 and a 1-year high of $13.10.
周三,aTyr Pharma的股票开盘报2.93美元。该公司的50日移动均线价格为3.49美元,200日移动均线价格为3.76美元。ATyr Pharma的一年低点为2.60美元,一年高位为13.10美元。
aTyr Pharma (NASDAQ:LIFE – Get Rating) last announced its quarterly earnings results on Monday, August 15th. The biotechnology company reported ($0.44) earnings per share for the quarter, missing the consensus estimate of ($0.43) by ($0.01). During the same quarter last year, the company earned ($0.64) EPS. Analysts anticipate that aTyr Pharma will post -1.81 earnings per share for the current fiscal year.
ATyr Pharma(纳斯达克:LIFE-GET评级)最近一次公布季度收益是在8月15日(星期一)。这家生物技术公司公布了本季度每股收益(0.44美元),低于普遍预期的(0.43美元)和(0.01美元)。去年同期,该公司每股收益为0.64美元。分析师预计,aTyr Pharma本财年的每股收益将达到1.81美元。
Insiders Place Their Bets
内部人士下注
Hedge Funds Weigh In On aTyr Pharma
对冲基金参与aTyr Pharma
Several large investors have recently bought and sold shares of LIFE. Tikvah Management LLC bought a new stake in shares of aTyr Pharma in the 4th quarter worth $9,157,000. Deep Track Capital LP purchased a new stake in aTyr Pharma in the 4th quarter valued at about $8,217,000. Stonepine Capital Management LLC lifted its position in shares of aTyr Pharma by 28.0% during the 4th quarter. Stonepine Capital Management LLC now owns 525,531 shares of the biotechnology company's stock worth $3,926,000 after buying an additional 114,996 shares in the last quarter. Alyeska Investment Group L.P. boosted its stake in shares of aTyr Pharma by 12.7% in the 1st quarter. Alyeska Investment Group L.P. now owns 760,798 shares of the biotechnology company's stock worth $4,070,000 after buying an additional 85,823 shares during the last quarter. Finally, GSA Capital Partners LLP bought a new position in shares of aTyr Pharma in the fourth quarter valued at approximately $439,000. 65.58% of the stock is currently owned by institutional investors.
几家大型投资者最近买卖了人寿的股票。Tikvah Management LLC在第四季度购买了价值915.7万美元的aTyr Pharma新股。Deep Track Capital LP在第四季度购买了aTyr Pharma的新股份,价值约8,217,000美元。Stonepine Capital Management LLC在第四季度将其在aTyr Pharma的股票头寸提高了28.0%。Stonepine Capital Management LLC现在拥有这家生物技术公司525,531股票,价值3926,000美元,上个季度又购买了114,996股票。Alyeska Investment Group L.P.在第一季度将其在aTyr Pharma的持股增加了12.7%。Alyeska Investment Group L.P.现在持有这家生物技术公司760,798股股票,价值4,070,000美元,在上个季度又购买了85,823股。最后,GSA Capital Partners LLP在第四季度购买了新的aTyr Pharma股票,价值约43.9万美元。65.58%的股票目前由机构投资者持有。
Wall Street Analyst Weigh In
华尔街分析师也加入进来
A number of research firms have commented on LIFE. Piper Sandler raised their price target on shares of aTyr Pharma from $11.00 to $14.00 and gave the stock an "overweight" rating in a report on Monday, August 15th. StockNews.com lowered aTyr Pharma from a "hold" rating to a "sell" rating in a research report on Wednesday, September 14th. Finally, HC Wainwright increased their price target on aTyr Pharma from $11.00 to $35.00 and gave the stock a "buy" rating in a report on Thursday, July 21st.
许多研究公司都对生活发表了评论。派珀·桑德勒在8月15日周一的一份报告中将aTyr Pharma的股票目标价从11.00美元上调至14.00美元,并给予该股“增持”评级。在9月14日星期三的一份研究报告中,StockNews.com将aTyr Pharma的评级从持有下调至卖出。最后,在7月21日星期四的一份报告中,HC Wainwright将aTyr Pharma的目标价从11.00美元上调至35.00美元,并给出了该股的“买入”评级。
About aTyr Pharma
关于阿泰尔制药公司
(Get Rating)
(获取评级)
aTyr Pharma, Inc, a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. The company's lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in Phase II clinical trial for pulmonary sarcoidosis; and in Phase 1b/2a clinical trial for treatment of other interstitial lung diseases (ILDs), such as chronic hypersensitivity pneumonitis and connective tissue disease related ILD.
ATyr Pharma,Inc.是一家生物疗法公司,在美国从事基于新免疫途径的药物的发现和开发。该公司的主要候选药物是efzofitimod,这是一种NRP2的选择性调节剂,正在进行肺结节病的第二阶段临床试验;以及1b/2a阶段的临床试验,用于治疗其他间质性肺部疾病,如慢性过敏性肺炎和与ILD相关的结缔组织疾病。
Recommended Stories
推荐故事
- Get a free copy of the StockNews.com research report on aTyr Pharma (LIFE)
- 3 Defensive Stocks With 60-Year Dividend Hike Streaks
- 3 Airline Stocks Stuck in a Holding Pattern
- Roku Stock is Down but Not Out
- If You're Hungry for Value, Take a Bite on Ruth's Hospitality Grp
- Is Ford Rolling To A Rebound After Its Q3 Warning
- 免费获取StockNews.com关于aTyr Pharma(LIFE)的研究报告
- 连续60年提高股息的3只防御性股票
- 3家航空公司股票陷入持有格局
- Roku股票下跌,但并未出局
- 如果你渴望价值,那就尝尝露丝的好客之道吧
- 福特在第三季度发出警告后是否正在反弹
Receive News & Ratings for aTyr Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for aTyr Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
接受aTyr Pharma Daily的新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯接收对aTyr Pharma和相关公司的最新新闻和分析师评级的每日简要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧